

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities, nor is it intended to invite any such offer or invitation. This announcement or any copy thereof may not be directly or indirectly brought into or distributed in the United States (including its territories and possessions, any state of the United States and the District of Columbia). In particular, this announcement does not constitute and is not an offer to sell any securities or a solicitation of an offer to purchase or subscribe for any securities in the United States or elsewhere. Securities may not be offered or sold in the United States unless registered or exempted from registration under the United States Securities Act of 1933, as amended. Any public offering of securities in the United States will be made only by means of a prospectus, which may be obtained from the issuer or the seller of the securities and contains detailed information about the issuer and its management as well as financial information. The Company does not intend to make a public offering of the securities referred to in this announcement in the United States.*



**GIANT BIOGENE HOLDING CO., LTD**

**巨子生物控股有限公司**

*(An exempted company incorporated in the Cayman Islands with limited liability)*

**(Stock code: 2367)**

**COMPLETION OF  
PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF  
NEW SHARES UNDER THE GENERAL MANDATE**

**Overall Coordinator and Placing Agent**

**Goldman  
Sachs**

**Financial Adviser**



Reference is made to the announcement of Giant Biogene Holding Co., Ltd (the “**Company**”) dated May 17, 2024 (the “**Announcement**”) in relation to the Vendor Placing and the Subscription. Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

### **Completion of Vendor Placing and Subscription of New Shares under General Mandate**

The Company is pleased to announce that completion of the Vendor Placing took place on May 21, 2024 and the completion of the Subscription took place on May 24, 2024. A total of 33,220,000 Shares held by the Top-up Vendor have been successfully placed at the Placing Price of HK\$49.40 per Share to not less than six professional, institutional and/or individual investors who (to the best of the knowledge, information and belief of the Directors, having made all reasonable enquiries), together with their respective ultimate beneficial owners, are third parties independent of and not connected with the Company or its connected persons. As far as the Company and Top-up Vendor are aware, none of the placees and their ultimate beneficial owners will become a substantial shareholder (as defined under the Listing Rules) of the Company as a result of the Vendor Placing and Subscription.

In connection with the Vendor Placing, a total of 33,220,000 Subscription Shares have been issued to the Top-up Vendor at the Subscription Price of HK\$49.40 per Share as all the conditions for the Subscription have been fulfilled. The net price for the Subscription (after deducting the commissions and estimated expenses) is estimated to be approximately HK\$48.97 per Subscription Share. The number of the Subscription Shares equal to the Shares disposed of by the Top-up Vendor in the Vendor Placing. The Subscription Shares represent approximately 3.23% of the issued share capital of the Company as enlarged by the Subscription. The net proceeds to the Company from the Subscription are approximately HK\$1,627 million, among which, (i) approximately 90%, or HK\$1,464.3 million, will be used for development of core business and its ecosystem, including but not limited to brand promotion, marketing and R&D investment; and (ii) approximately 10%, or HK\$162.7 million, will be used for replenishment of liquidity and general corporate purposes.

## Effects of the Vendor Placing and Subscription on the Shareholding Structure of the Company

The table below sets forth the shareholding structure of the Company (i) immediately before the completion of the Vendor Placing and Subscription; (ii) immediately after the completion of the Vendor Placing but before the completion of the Subscription, and (iii) immediately after the completion of the Vendor Placing and Subscription.

Shareholder	Immediately before the completion of the Vendor Placing and Subscription		Immediately after the completion of the Vendor Placing but before the completion of the Subscription		Immediately after the completion of the Vendor Placing and Subscription	
	Number of Shares held	Percentage (%)	Number of Shares held	Percentage (%)	Number of Shares held	Percentage (%)
Top-up Vendor Places	581,104,935	58.40	547,884,935	55.06	581,104,935	56.52
Other Shareholders	–	0.00	33,220,000	3.34	33,220,000	3.23
	413,895,065	41.60	413,895,065	41.60	413,895,065	40.25
<b>Total</b>	<b>995,000,000</b>	<b>100.0</b>	<b>995,000,000</b>	<b>100.0</b>	<b>1,028,220,000</b>	<b>100.0</b>

*Note:* The percentages may not add up to 100% due to rounding.

By order of the Board  
**Giant Biogene Holding Co., Ltd**  
**Yan Jianya**  
*Chairman of the Board*

Xi'an, the PRC  
 May 24, 2024

*As at the date of this announcement, the Board comprises Mr. Yan Jianya, Ms. Ye Juan, Ms. Fang Juan, Ms. Zhang Huijuan and Ms. Yan Yubo as executive directors, and Mr. Huang Jin, Mr. Shan Wenhua and Ms. Wong Sze Wing as independent non-executive directors.*